Abbott India: JPMorgan cuts pharma stock’s target price; Check the details

Synopsis: Brokerage downgrade with a 19 percent target price cut, coupled with growth concerns and rising disruption risks, shakes confidence as a weak pipeline and leadership churn add to uncertainty over the company’s future trajectory.

The article outlines key concerns impacting the company’s outlook, including a sharp target price cut, valuation de-rating, weak product pipeline, rising competitive threats from new therapies, and leadership instability, all of which signal moderating growth prospects and increased uncertainty around its future performance.

With a market capitalization of Rs 54,855 crore, Abbott India Ltd’s share closed at Rs 25,815 per share, down by 0.18 percent from its previous day’s close. The share has given a return of 72 percent over the last five years, as it trades at a fairly valued P/E of 36x compared to the industry average.

Brokerage Views

JPMorgan has cut the target price by 19 percent to Rs 27,500 from Rs 34,000, indicating reduced upside potential of just 6 percent amid weakening growth outlook and rising business uncertainties.

Rationale of the target Cut

Target Price Cut by 19 percent: JPMorgan has cut its target price to Rs 27,500 from Rs 34,000, implying a 19 percent downgrade. The revision reflects weaker earnings visibility and softer medium-term growth expectations, suggesting limited upside potential as operational performance and demand outlook remain under pressure.

Valuation Multiple De-rated: The brokerage has reduced the valuation multiple, indicating concerns beyond short-term challenges. This de-rating signals a structural reassessment of growth prospects, implying that the market may assign lower premium valuations going forward due to moderating long-term earnings potential.

Weak Product Pipeline Impact: A muted product pipeline, combined with the phase-out of its key insulin brand, is expected to impact revenue growth. The lack of meaningful new launches could weaken business momentum, limiting the company’s ability to offset declining contributions from its established portfolio.

GLP-1 Therapy Disruption Risk: Rising adoption of GLP-1 therapies poses a structural threat to the company’s core diabetes portfolio. As treatment preferences shift, this could impact demand for existing products, creating uncertainty around long-term growth visibility in one of its most critical therapeutic segments.

Leadership Instability Concerns: Frequent leadership transitions, including three managing director exits in four years, raise concerns about strategic continuity. Such instability may affect execution, decision-making, and long-term planning, potentially hindering the company’s ability to deliver consistent growth and maintain investor confidence.

Verdict: Investors should adopt a cautious approach, closely tracking product pipeline developments, competitive intensity from GLP-1 therapies, and leadership stability. While long-term fundamentals may remain intact, near-term uncertainties warrant a wait-and-watch stance, with fresh exposure considered only after clearer growth visibility and consistent execution trends emerge.

About the Company

Abbott India Limited is a leading, publicly listed pharmaceutical company and subsidiary of U.S.-based Abbott Laboratories, headquartered in Mumbai. Operating for over 115 years in India, it focuses on high-quality branded generic medicines in therapy areas like women’s health, gastroenterology, metabolic systems, and CNS, supported by a major manufacturing plant in Goa.

Financial highlights: The revenue from operations grew by 6.8 percent to Rs 1,724 crore in Q3 FY26, corresponding to the same quarter in the last financial year, and the operating margin stayed flat at 27 percent YoY. Accompanied by a net profit growth of 4 percent to Rs 376 crore in Q3 FY26 from Rs 361 crore in Q3 FY25, resulting in EPS growth of 4.2 percent YoY to Rs 176.93 per share in Q3 FY26.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Abbott India: JPMorgan cuts pharma stock’s target price; Check the details appeared first on Trade Brains.